Back to top
more

SpringWorks Therapeutics (SWTX)

(Delayed Data from NSDQ)

$41.71 USD

41.71
570,658

+0.78 (1.91%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SWTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

SpringWorks Therapeutics [SWTX]

Reports for Purchase

Showing records 161 - 180 ( 198 total )

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 161

07/22/2020

Daily Note

Pages: 5

Niro is ?the One? Gamma Secretase Inhibitor

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 162

07/15/2020

Company Report

Pages: 4

Belantamab Receives Unanimous Recommendation for Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 163

07/14/2020

Company Report

Pages: 7

FDA Questions Belantamab''s Risk/Reward Profile; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 164

06/23/2020

Company Report

Pages: 7

Encouraging Preclinical Lifirafenib + Mirdametinib Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 165

06/01/2020

Company Report

Pages: 5

BCMA Competitive Landscape Updates From ASCO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 166

05/13/2020

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 167

05/13/2020

Company Report

Pages: 5

ASCO and AACR Data Updates Approaching; 1Q20 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 168

05/13/2020

Company Report

Pages: 7

Works and Days

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 169

04/28/2020

Company Report

Pages: 10

Mirdametinib + Lifirafenib Risk Mitigation via Competitor Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 170

04/14/2020

Company Report

Pages: 4

Adjusting Our Mirdametinib Pricing Assumptions Following Koselugo FDA Approval; Modulating PT to $58

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 171

04/13/2020

Company Report

Pages: 5

Selumetinib Approval Paves the Way for More with Mirda

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 172

04/02/2020

Industry Report

Pages: 53

2020 TKI Outlook: COVID-19 Notwithstanding, We Still Like the Setup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 173

03/26/2020

Daily Note

Pages: 9

Biotechnology- From Underneath the Rubble Sing a Rebel Song

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 174

03/26/2020

Industry Report

Pages: 9

From Underneath The Rubble Sing a Rebel Song

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 175

03/19/2020

Company Report

Pages: 4

Polymorph Patent Extends Commercial Window to 2039; Upgrading to Buy; Raising PT to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 176

03/19/2020

Daily Note

Pages: 5

Patent Springs a Long Life for Niro

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 177

03/19/2020

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 178

03/16/2020

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 179

03/16/2020

Company Report

Pages: 8

2019 Financial Results Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: SpringWorks Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 180

03/16/2020

Company Report

Pages: 6

No Winter Lasts Forever...

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party
// eof